Impact of Reimbursement Cuts on the Sustainability and Accessibility of Dopamine Transporter Imaging

Matthew F. Covington, Natalie A. McMillan, Phillip H Kuo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Dopamine transporter single-photon emission computed tomography imaging utilizing iodine-123 ioflupane is accurate for differentiation of Parkinson disease from essential tremor. This study evaluates how reimbursement for I-123 ioflupane imaging changed between 2011 (year of FDA approval) and 2014 (year after loss of pass-through status for hospital-based outpatient imaging from CMS). Methods: I-123 ioflupane reimbursement data for our institution's hospital-based imaging were compared between two periods: (1) July 2011 to October 2012, and (2) 2014. For each time period separately and in combination, averages and ranges of reimbursement for private insurance and CMS were analyzed and compared. A model to ensure recouping of radiopharmaceutical costs was developed. Results: Review yielded 247 studies from July 2011 to October 2012 and 94 studies from 2014. Average reimbursement per study fell from $2,469 (US dollars) in 2011 to 2012 to $1,657 in 2014. CMS reduced average reimbursement by $1,148 in 2014 because of loss of radiopharmaceutical pass-through status. Average reimbursements from CMS versus private payors markedly differed in 2011 to 2012 at $2,266 versus $2,861, respectively, and in 2014 at $1,118 versus $3,470, respectively. Between 2011 to 2012 and 2014, the CMS percentage increased from 54% to 78%. Assuming that I-123 ioflupane cost $2,000, our model based on 2014 data predicts a practice with greater than 60% CMS patients would no longer recover radiopharmaceutical costs. Conclusions: Reimbursement levels, payor mix, scanner location, and radiopharmaceutical costs are all critical, variable factors for modeling the financial viability of I-123 ioflupane imaging and, by extrapolation, future radiopharmaceuticals.

Original languageEnglish (US)
JournalJournal of the American College of Radiology
DOIs
StateAccepted/In press - 2016

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Radiopharmaceuticals
Costs and Cost Analysis
Essential Tremor
Insurance
Single-Photon Emission-Computed Tomography
Iodine
Parkinson Disease
Outpatients
ioflupane

Keywords

  • Dopamine transporter imaging
  • HOPPS
  • Imaging access
  • Ioflupane
  • Medicare reimbursement
  • Radiopharmaceutical cost

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Impact of Reimbursement Cuts on the Sustainability and Accessibility of Dopamine Transporter Imaging. / Covington, Matthew F.; McMillan, Natalie A.; Kuo, Phillip H.

In: Journal of the American College of Radiology, 2016.

Research output: Contribution to journalArticle

@article{7fbbbae7b1124bedb5fb95b4d3ea4351,
title = "Impact of Reimbursement Cuts on the Sustainability and Accessibility of Dopamine Transporter Imaging",
abstract = "Purpose: Dopamine transporter single-photon emission computed tomography imaging utilizing iodine-123 ioflupane is accurate for differentiation of Parkinson disease from essential tremor. This study evaluates how reimbursement for I-123 ioflupane imaging changed between 2011 (year of FDA approval) and 2014 (year after loss of pass-through status for hospital-based outpatient imaging from CMS). Methods: I-123 ioflupane reimbursement data for our institution's hospital-based imaging were compared between two periods: (1) July 2011 to October 2012, and (2) 2014. For each time period separately and in combination, averages and ranges of reimbursement for private insurance and CMS were analyzed and compared. A model to ensure recouping of radiopharmaceutical costs was developed. Results: Review yielded 247 studies from July 2011 to October 2012 and 94 studies from 2014. Average reimbursement per study fell from $2,469 (US dollars) in 2011 to 2012 to $1,657 in 2014. CMS reduced average reimbursement by $1,148 in 2014 because of loss of radiopharmaceutical pass-through status. Average reimbursements from CMS versus private payors markedly differed in 2011 to 2012 at $2,266 versus $2,861, respectively, and in 2014 at $1,118 versus $3,470, respectively. Between 2011 to 2012 and 2014, the CMS percentage increased from 54{\%} to 78{\%}. Assuming that I-123 ioflupane cost $2,000, our model based on 2014 data predicts a practice with greater than 60{\%} CMS patients would no longer recover radiopharmaceutical costs. Conclusions: Reimbursement levels, payor mix, scanner location, and radiopharmaceutical costs are all critical, variable factors for modeling the financial viability of I-123 ioflupane imaging and, by extrapolation, future radiopharmaceuticals.",
keywords = "Dopamine transporter imaging, HOPPS, Imaging access, Ioflupane, Medicare reimbursement, Radiopharmaceutical cost",
author = "Covington, {Matthew F.} and McMillan, {Natalie A.} and Kuo, {Phillip H}",
year = "2016",
doi = "10.1016/j.jacr.2016.04.002",
language = "English (US)",
journal = "Journal of the American College of Radiology",
issn = "1558-349X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Impact of Reimbursement Cuts on the Sustainability and Accessibility of Dopamine Transporter Imaging

AU - Covington, Matthew F.

AU - McMillan, Natalie A.

AU - Kuo, Phillip H

PY - 2016

Y1 - 2016

N2 - Purpose: Dopamine transporter single-photon emission computed tomography imaging utilizing iodine-123 ioflupane is accurate for differentiation of Parkinson disease from essential tremor. This study evaluates how reimbursement for I-123 ioflupane imaging changed between 2011 (year of FDA approval) and 2014 (year after loss of pass-through status for hospital-based outpatient imaging from CMS). Methods: I-123 ioflupane reimbursement data for our institution's hospital-based imaging were compared between two periods: (1) July 2011 to October 2012, and (2) 2014. For each time period separately and in combination, averages and ranges of reimbursement for private insurance and CMS were analyzed and compared. A model to ensure recouping of radiopharmaceutical costs was developed. Results: Review yielded 247 studies from July 2011 to October 2012 and 94 studies from 2014. Average reimbursement per study fell from $2,469 (US dollars) in 2011 to 2012 to $1,657 in 2014. CMS reduced average reimbursement by $1,148 in 2014 because of loss of radiopharmaceutical pass-through status. Average reimbursements from CMS versus private payors markedly differed in 2011 to 2012 at $2,266 versus $2,861, respectively, and in 2014 at $1,118 versus $3,470, respectively. Between 2011 to 2012 and 2014, the CMS percentage increased from 54% to 78%. Assuming that I-123 ioflupane cost $2,000, our model based on 2014 data predicts a practice with greater than 60% CMS patients would no longer recover radiopharmaceutical costs. Conclusions: Reimbursement levels, payor mix, scanner location, and radiopharmaceutical costs are all critical, variable factors for modeling the financial viability of I-123 ioflupane imaging and, by extrapolation, future radiopharmaceuticals.

AB - Purpose: Dopamine transporter single-photon emission computed tomography imaging utilizing iodine-123 ioflupane is accurate for differentiation of Parkinson disease from essential tremor. This study evaluates how reimbursement for I-123 ioflupane imaging changed between 2011 (year of FDA approval) and 2014 (year after loss of pass-through status for hospital-based outpatient imaging from CMS). Methods: I-123 ioflupane reimbursement data for our institution's hospital-based imaging were compared between two periods: (1) July 2011 to October 2012, and (2) 2014. For each time period separately and in combination, averages and ranges of reimbursement for private insurance and CMS were analyzed and compared. A model to ensure recouping of radiopharmaceutical costs was developed. Results: Review yielded 247 studies from July 2011 to October 2012 and 94 studies from 2014. Average reimbursement per study fell from $2,469 (US dollars) in 2011 to 2012 to $1,657 in 2014. CMS reduced average reimbursement by $1,148 in 2014 because of loss of radiopharmaceutical pass-through status. Average reimbursements from CMS versus private payors markedly differed in 2011 to 2012 at $2,266 versus $2,861, respectively, and in 2014 at $1,118 versus $3,470, respectively. Between 2011 to 2012 and 2014, the CMS percentage increased from 54% to 78%. Assuming that I-123 ioflupane cost $2,000, our model based on 2014 data predicts a practice with greater than 60% CMS patients would no longer recover radiopharmaceutical costs. Conclusions: Reimbursement levels, payor mix, scanner location, and radiopharmaceutical costs are all critical, variable factors for modeling the financial viability of I-123 ioflupane imaging and, by extrapolation, future radiopharmaceuticals.

KW - Dopamine transporter imaging

KW - HOPPS

KW - Imaging access

KW - Ioflupane

KW - Medicare reimbursement

KW - Radiopharmaceutical cost

UR - http://www.scopus.com/inward/record.url?scp=84969642675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969642675&partnerID=8YFLogxK

U2 - 10.1016/j.jacr.2016.04.002

DO - 10.1016/j.jacr.2016.04.002

M3 - Article

C2 - 27233911

AN - SCOPUS:84969642675

JO - Journal of the American College of Radiology

JF - Journal of the American College of Radiology

SN - 1558-349X

ER -